thrombospondin-1 mimetic (ABT-510) / AbbVie - LARVOL DELTA

Discovery of Fatty Acid Translocase CD36-Targeting Near-Infrared Fluorescent Probe Enables Visualization and Imaging-Guided Surgery for Glioma. (PubMed, Anal Chem) - "Moreover, pathological analysis of tumor and healthy brain tissues unveiled well-defined tumor boundaries, highlighting the capacity of the MPA-Pip-abt-510 probe to precisely visualize the CD36 protein at the molecular level. Given its rapid tumor-targeting abilities, durable retention, and accurate outlining of tumor boundaries, MPA-Pip-abt-510 emerges as a promising CD36-targeted fluorescence contrast agent and expands the toolbox of glioma fluorescent probes for surgical navigation."

Journal • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD36 • SCARB1

Novel Surgical Model of Thoracic Aortic Aneurysm Mediated by Vasa Vasorum Inhibition (AHA 2024) - "We tested this hypothesis in a rabbit model via peri-adventitial delivery of ABT-510, a thrombospondin peptide mimetic.The ascending aorta was exposed in New Zealand White rabbits (n=16) and treated with ABT-510 proximally and a vehicle control distally...Our study findings demonstrate a novel, clinically relevant model for thoracic aortic aneurysm through vasa vasorum inhibition that recapitulates features of cystic medial degeneration. This translational model could enable development of targeted, pro-regenerative therapies that restore perfusion to the aortic wall."

Cardiovascular

Thrombospondin-1 Deficient Exacerbates the Pathogenesis of Imiquimod-Induced Psoriasis (EADV 2024) - "Introduction & Objectives: Psoriasis is a chronic, relapsing inflammatory skin disorder, characterized by as silver scaling erythematous plaques due to epidermal hyperplasia, aberrant differentiation of keratinocytes, and increased angiogenesis. Our findings underscore TSP-1 ’ s pivotal regulatory role in IMQ-induced psoriasiform skin inflammation, thus, wu suggested that TSP-1 may act as an important endogenous negative regulator of psoriasis pathogenesis and may be developed as a novel therapeutic strategy of psoriasis."

Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • IL23A • THBS1

Visualization of nonsmall-cell lung cancer by near-infrared fluorescence imaging with tumor-targeting peptide ABT-510. (PubMed, Bioorg Chem) - "High MPA-ABT-510 accumulation was evident in A549 intestinal metastases models, as evidenced by tumor-to-colorectal fluorescence ratios of 4.27 ± 0.11. MPA-ABT-510 exhibits superior imaging capabilities with minimal safety concerns, so it is a promising candidate for NSCLC surgical navigation."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD36 • SCARB1

API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - P2 | N=252 | Completed | Sponsor: Genentech, Inc. | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders • APOE • APP • CSF P-tau

Preclinical Evaluation of CD36-Targeting Antiangiogenic Peptide ABT-510 for Near-Infrared Fluorescence Molecular Imaging of Colorectal Cancer. (PubMed, Anal Chem) - "Furthermore, MPA-PEG-r-ABT-510 exhibited an antiangiogenic effect via tube information assay with human umbilical vein endothelial cells. Overall, MPA-PEG-r-ABT-510 presents rapid and precise tumor delineation characteristics, thereby making it a desirable tool for CRC imaging and surgical navigation."

Journal • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD36

API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - P2 | N=252 | Active, not recruiting | Sponsor: Genentech, Inc. | Trial completion date: Dec 2022 ➔ Aug 2023

Preclinical • Trial completion date • Alzheimer's Disease • CNS Disorders • APOE

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease (clinicaltrials.gov) - P2 | N=150 | Completed | Sponsor: Hoffmann-La Roche | Recruiting ➔ Completed

Preclinical • Tau PET • Trial completion • Alzheimer's Disease • CNS Disorders

Thrombospondin-1 Plays a Major Pathogenic Role in Experimental and Human Bronchopulmonary Dysplasia. (PubMed, Am J Respir Crit Care Med) - "Thrombospondin-1 inhibits alveologenesis in neonatal rats, in part via up-regulated activity of TGF-β1. Observations in human lung suggest a similar pathogenic role for thrombospondin-1 in infants at-risk for BPD."

Journal • Bronchopulmonary Dysplasia • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • TGFB1 • THBS1

API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - P2; N=252; Active, not recruiting; Sponsor: Genentech, Inc.; Trial primary completion date: Dec 2022 ➔ Mar 2022

Preclinical • Trial primary completion date • Alzheimer's Disease • CNS Disorders • APOE • MRI

API ADAD Colombia : A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort (clinicaltrials.gov) - P2; N=252; Active, not recruiting; Sponsor: Genentech, Inc.; Trial completion date: Mar 2022 ➔ Dec 2022; Trial primary completion date: Mar 2022 ➔ Dec 2022

Preclinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders • APOE • MRI

FSH promotes the proliferation of sheep granulosa cells by inhibiting the expression of TSP1. (PubMed, Anim Biotechnol) - "In contrast, TSP1 mimetic peptide, ABT510, offsets the proliferation of sheep granulosa cells. Different signaling pathway inhibitors all promoted FSH-inhibited TSP1 expression, but each inhibitor had different effects on TSP1. Among them, the PI3K and ERK pathway inhibitors significantly promoted TSP1 expression and inhibited the proliferation of sheep granulosa cells."

Journal • THBS1

Facile Preparation of Peptides with C-Terminal N-Alkylamide via Radical-Initiated Dethiocarboxylation. (PubMed) - Chem Pharm Bull (Tokyo) - "This method enables the introduction of various alkyl groups to C-terminal amides simply by replacing the amino acid building block. Its application to the preparation of anti-cancer drug ABT-510 is also reported."

Journal • Biosimilar • Oncology

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease (clinicaltrials.gov) - P2; N=150; Recruiting; Sponsor: Genentech, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • Tau PET

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease (clinicaltrials.gov) - P2; N=150; Not yet recruiting; Sponsor: Genentech, Inc.

New P2 trial